Stock Scorecard



Stock Summary for Polypid Ltd (PYPD) - $3.54 as of 10/7/2025 7:48:41 AM EST

Total Score

10 out of 30

Safety Score

16 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PYPD

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PYPD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PYPD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PYPD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PYPD (16 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for PYPD

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress - PolyPid ( NASDAQ:PYPD ) 9/30/2025 12:45:00 PM
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress 9/30/2025 12:45:00 PM
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference - PolyPid ( NASDAQ:PYPD ) 9/17/2025 12:44:00 PM
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference 9/17/2025 12:44:00 PM
Cisco To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Thursday - Celanese ( NYSE:CE ) , Cisco Systems ( NASDAQ:CSCO ) 8/14/2025 6:01:00 PM
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results 8/13/2025 11:30:00 AM
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer 8/12/2025 12:00:00 PM
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - PolyPid ( NASDAQ:PYPD ) 6/16/2025 11:20:00 PM
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results 6/16/2025 11:20:00 PM
PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention 6/11/2025 1:42:00 PM

Financial Details for PYPD

Company Overview

Ticker PYPD
Company Name Polypid Ltd
Country USA
Description PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies utilizing its proprietary Polymer Lipid Encapsulation Matrix (PLEX) technology. Focused on addressing significant unmet medical needs, PolyPid's pipeline includes products designed to enhance the treatment of local infections and improve surgical outcomes. The company is headquartered in Petah Tikva, Israel, positioning it within a vibrant biotech ecosystem and fostering potential collaborations and advancements in health care.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 11/12/2025

Stock Price History

Last Day Price 3.54
Price 4 Years Ago 172.20
Last Day Price Updated 10/7/2025 7:48:41 AM EST
Last Day Volume 78,261
Average Daily Volume 57,699
52-Week High 3.93
52-Week Low 2.30
Last Price to 52 Week Low 53.91%

Valuation Measures

Trailing PE N/A
Industry PE 22.22
Sector PE 41.70
5-Year Average PE -1.18
Free Cash Flow Ratio 3.22
Industry Free Cash Flow Ratio 14.45
Sector Free Cash Flow Ratio 30.25
Current Ratio Most Recent Quarter 2.28
Total Cash Per Share 1.10
Book Value Per Share Most Recent Quarter 1.31
Price to Book Ratio 2.69
Industry Price to Book Ratio 29.58
Sector Price to Book Ratio 32.02
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 44.16
Sector Price to Sales Ratio Twelve Trailing Months 20.22
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 15,897,200
Market Capitalization 56,276,088
Institutional Ownership 41.20%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -21.61%
Reported EPS 12 Trailing Months -3.77
Reported EPS Past Year -1.48
Reported EPS Prior Year -4.91
Net Income Twelve Trailing Months -34,525,000
Net Income Past Year -29,022,000
Net Income Prior Year -23,865,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 17,448,000
Total Cash Past Year 15,641,000
Total Cash Prior Year 5,609,000
Net Cash Position Most Recent Quarter 17,067,000
Net Cash Position Past Year 15,007,000
Long Term Debt Past Year 634,000
Long Term Debt Prior Year 6,379,000
Total Debt Most Recent Quarter 381,000
Equity to Debt Ratio Past Year 0.92
Equity to Debt Ratio Most Recent Quarter 0.98
Total Stockholder Equity Past Year 7,684,000
Total Stockholder Equity Prior Year -2,096,000
Total Stockholder Equity Most Recent Quarter 20,476,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 0
Free Cash Flow Per Share Twelve Trailing Months 0.00
Free Cash Flow Past Year -22,039,000
Free Cash Flow Prior Year -17,432,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal -0.01
20-Day Bollinger Lower Band 3.05
20-Day Bollinger Middle Band 3.41
20-Day Bollinger Upper Band 3.77
Beta 1.50
RSI 57.29
50-Day SMA 7.34
150-Day SMA 0.00
200-Day SMA 37.21

System

Modified 10/7/2025 7:48:44 AM EST